In Brief: FDA Gastrointestinal Drugs Advisory Committee
FDA Gastrointestinal Drugs Advisory Committee: Meeting July 12 to discuss Lemmon's NDA 20-458 for zinc acetate for treatment of Wilson's disease and draft "Points to Consider" on H. pylori studies to prevent peptic ulcer recurrence. The meeting will take place at the Holiday Inn-Bethesda, Md., beginning at 9 a.m. A joint meeting of the GI Drugs committee with the Nonprescription Drugs Advisory Committee will take place on July 13 to discuss Glaxo's NDA 20-520 for an Rx-to-OTC switch of Zantac 75 for treatment of heartburn. The meeting begins at 8:30 a.m. in conference rooms D&E of FDA's Parklawn building...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth